UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2144-13
Program Prior Authorization/Medical Necessity
Medication Ilumya® (tildrakizumab-asmn)*
*Ilumya is excluded from coverage for the majority of our benefits
P&T Approval Date 5/2018, 2/2019, 9/2019, 5/2020, 5/2021, 6/2021, 12/2021, 11/2022,
1/2023, 4/2023, 7/2023, 10/2024, 4/2025
Effective Date 6/1/2025
1. Background:
Ilumya (tildrakizumab) is an interleukin-23 antagonist indicated for the treatment of adults
with moderate to severe plaque psoriasis who are candidates for systemic therapy or
phototherapy.
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Ilumya will be approved based on the following criteria:
(1) Submission of medical records (e.g., chart notes, laboratory values) documenting
all of the following:
(a) Diagnosis of chronic moderate to severe plaque psoriasis
-AND-
(b) One of the following:
i. All of the following:
a. Greater than or equal to 3 % body surface area involvement,
palmoplantar, facial, genital involvement, or severe scalp psoriasis
-AND-
b. History of failure to one of the following topical therapies unless
contraindicated or clinically significant adverse effects are
experienced (document drug, date, and duration of trial):
• Corticosteroids (e.g., betamethasone, clobetasol, desonide)
• Vitamin D analogs (e.g., calcitriol, calcipotriene)
• Tazarotene
• Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
© 2025 UnitedHealthcare Services Inc.
1
• Anthralin
• Coal tar
-AND-
c. History of failure to a 3 month trial of methotrexate at maximally
indicated dose, unless contraindicated or clinically significant adverse
effects are experienced (document date and duration of trial)b
-OR-
ii. Patient has been previously treated with a targeted immunomodulator
FDA-approved for the treatment of plaque psoriasis as documented by
claims history or submission of medical records (Document drug, date,
and duration of therapy) [e.g., Cimzia (certolizumab), adalimumab,
Otezla (apremilast), Skyrizi (risankizumab), ustekinumab, Tremfya
(guselkumab), Enbrel (etanercept)]
-AND-
(c) History of failure, contraindication, or intolerance to three of the following
preferred products (document drug, date, and duration of trial):
i. One of the preferred adalimumab productsc
ii. Cimzia (certolizumab)
iii. Cosentyx (secukinumab)
iv. Enbrel (etanercept)
v. Skyrizi (risankizumab)
vi. Sotyktu (deucravacitinib)
vii. One of the preferred ustekinumab productsc
viii. Tremfya (guselkumab)
-AND-
(d) Patient is not receiving Ilumya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Siliq (brodalumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]
-AND-
(e) Prescribed by or in consultation with a dermatologist
Authorization will be issued for 12 months.
2. Reauthorization
© 2025 UnitedHealthcare Services Inc.
2
a. Ilumya will be approved based on all of the following criteria:
(1) Documentation of positive clinical response to Ilumya therapy
-AND-
(2) Patient is not receiving Ilumya in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz
(ixekizumab), Siliq (brodalumab), Xeljanz (tofacitinib), Olumiant (baricitinib),
Rinvoq (upadacitinib), Otezla (apremilast)]
Reauthorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.
c For a list of preferred products please reference drug coverage tools.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• *Ilumya is excluded from coverage for the majority of our benefits
• Supply limits may be in place.
4. References:
1. Ilumya [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; December
2022.
2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of
psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care
for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.
3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of
psoriasis and psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for
treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of
psoriasis with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.
5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and
photochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.
6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with
traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.
© 2025 UnitedHealthcare Services Inc.
3
7. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris –
update 2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm
Venereol 2015;29:2277-94.
8. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care
for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the
treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based
conclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-74.
9. Gossec L, et al; European League Against Rheumatism (EULAR) recommendations for the
management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum
Dis 2016;75:499-510.
10. Menter A, Strober BE, Kaplan DH et al. Joint AAD-NPF guidelines of care for the
management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019:80:1029-
72.
Program Prior Authorization/Medical Necessity-Ilumya (tildrakizumab)
Change Control
Date Change
5/2018 New program
2/2019 Annual review. Updated background and criteria adding Cimzia to list
of preferred products for the treatment of plaque psoriasis.
9/2019 Updated criteria adding Skyrizi as preferred medication. Added
coverage exclusion statement. Updated references.
5/2020 Updated formatting without change to clinical intent
5/2021 Annual review. Remove prescriber requirement for reauthorization.
Removed drug documentation where only one drug is required.
Updated references.
6/2021 Added coverage criteria for patients previously treated with a biologic
DMARD.
12/2021 Updated the following with no change to clinical intent: updated
conventional DMARD bypass language for psoriasis, removed
“biologic” from required preferred product criteria language and
updated CT/KY footnote.
11/2022 Added Enbrel as a preferred product step option. Added Enbrel as an
example where appropriate. Added Mississippi to state mandate
footnote. Updated reference.
1/2023 Updated step therapy requirements to Humira or Amjevita. Updated
listed examples from Humira to adalimumab.
4/2023 Updated step therapy requirement from Humira or Amjevita to one of
the preferred adalimumab products and added the footnote “For a list of
preferred adalimumab products please reference drug coverage tools.”
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
10/2024 Updated step requirement noting Adalimumab-adaz (unbranded
Hyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab
products with no change to clinical intent. Removed preferred
adalimumab footnote. Added Sotyktu as step therapy agent. Moved
Cosentyx to preferred step agent and changed step to three agents.
Updated state mandate footnote and reference.
4/2025 Removed examples for adalimumab in step therapy. Changed Stelara
step therapy to “One of the preferred ustekinumab productsc”. Changed
© 2025 UnitedHealthcare Services Inc.
4
Stelara example to Ustekinumab. Added the footnote “For a list of
preferred products please reference drug coverage tools.”
© 2025 UnitedHealthcare Services Inc.
5